Thus, targeting IL-6 and/or TNFα offers approaches to the diagnosis and treatment of different primary diseases (e.g., rheumatoid arthritis and sarcopenia) and health-compromising secondary conditions (e.g., cancer cachexia and post-infectious acute respiratory distress syndrome, ARDS). Here, IL6 is linked to acute respiratory distress syndrome.